Virtus Investment Advisers, Inc. Eli Lilly & CO Transaction History

Virtus Investment Advisers, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $117,428 - $147,264	-162 Reduced 36.0%	288 $260,000
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $266,490 - $356,526	450 New	450 $350,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $247,857 - $282,459	836 New	836 $270,000
Q1 2018 May 15, 2018	SELL	$74.21 - $87.6 $303,370 - $358,108	-4,088 Closed	0 $0
Q4 2017 Feb 26, 2018	SELL	$81.94 - $87.89 $1.31 Million - $1.4 Million	-15,971 Reduced 79.62%	4,088 $345,000
Q4 2017 Feb 14, 2018	BUY	$81.94 - $87.89 $1.64 Million - $1.76 Million	20,059	20,059 $346,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.